-
22 Octobre 2025
-
22 Octobre 2025
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
PARIS AND MARSEILLE, FRANCE, 22 October 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) and ImCheck Therapeutics today announced they have entered into a definitive share purchase agreement in which Ipsen will acquire all issued and outstanding shares of ImChec...
-
23 Octobre 2025
-
23 Octobre 2025
Ipsen launches educational initiative to support teens and young adults moving from pediatric to adult healthcare
CAMBRIDGE, MA, 23 OCTOBER 2025 - Ipsen, a global biopharmaceutical company, today announced a new initiative aimed at increasing awareness and education around the transition from pediatric to adult healthcare, which typically occurs around ages 18 to 21 a...
-
22 Décembre 2025
-
22 Décembre 2025
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
PARIS, FRANCE; 22 DECEMBER 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today an exclusive licensing agreement for global rights outside of Greater China, for SIM0613, an antibody-drug conjugate (ADC) with best-in-class potential. Targeting the LRRC1...
-
31 Juillet 2025
-
31 Juillet 2025
Ipsen delivers strong results in the first half of 2025 and upgrades its full-year guidance
“Our half year results reflect continued strong momentum, with growth across all three therapeutic areas, particularly in our rare liver disease franchise, which is expanding rapidly and progressing well,” said David Loew, Chief Executive Officer, Ipse...
-
18 Mars 2026
-
18 Mars 2026
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
PARIS, FRANCE, 18 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today the presentation of new preclinical data across multiple early development programs currently in Phase I clinical trials, at the American Association of Cancer Research (AACR)...
-
06 Mai 2025
-
06 Mai 2025
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation
PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & Transformation, effective May 14, 2025. She will se...
-
09 Juillet 2026
-
09 Juillet 2026
Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.
PARIS, FRANCE – 9 JULY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced positive topline results from its Phase III BEOND migraine program evaluating Dysport® (abobotulinumtoxinA) for the prevention of episodic (E-BEOND) and chronic migraine (...
-
16 Mai 2026
-
16 Mai 2026
Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction
PARIS, FRANCE, 16 May 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) today presented the first corabotase data (n=183) for moderate-to- severe glabellar lines at the 2026 Scale Symposium in Nashville, TN. Corabotase is Ipsen’s first-in-class recombinant n...
-
02 Mai 2024
-
02 Mai 2024
Ipsen appoints Keira Driansky as EVP, President of North America
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the Executiv...
-
23 Juillet 2025
-
23 Juillet 2025
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:...